ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Vaidyane Ayurved Laboratories's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹83 Mil.
Vaidyane Ayurved Laboratories's average Total Assets over the quarter that ended in Mar. 2026 was ₹933 Mil. Therefore, Vaidyane Ayurved Laboratories's annualized ROA % for the quarter that ended in Mar. 2026 was 8.91%.
The historical rank and industry rank for Vaidyane Ayurved Laboratories's ROA % or its related term are showing as below:
NSE:MADHAVBAUG'
s ROA % Range Over the Past 10 Years
Min: -1.92 Med: 6.07 Max: 10.24
Current: 10.24
During the past 8 years, Vaidyane Ayurved Laboratories's highest ROA % was 10.24%. The lowest was -1.92%. And the median was 6.07%.
NSE:MADHAVBAUG's ROA % is ranked better than 83.78% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs NSE:MADHAVBAUG: 10.24
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Vaidyane Ayurved Laboratories ROA % Related Terms
Vaidyane Ayurved Laboratories ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's ROA % distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a ROA % of 8.91% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vaidyane Ayurved Laboratories and its competitors. This is 47% above median its historical median of 6.07. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #163 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 16.2%.
Is Vaidyane Ayurved Laboratories' ROA % too high?
Vaidyane Ayurved Laboratories' current ROA % of 8.91% is 47% above median its 10-year median of 6.07. The Drug Manufacturers industry median ROA % is 2.72. Vaidyane Ayurved Laboratories' value of 8.91% is 227.6% above this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #163 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #163 out of 1005 companies for ROA %. This places Vaidyane Ayurved Laboratories in the top 16% of its industry — outperforming the majority of peers. The industry median ROA % is 2.72. Vaidyane Ayurved Laboratories' value of 8.91% is 227.6% above this benchmark. While the company's 10-year median is 6.07 vs. the industry median of 2.72, Vaidyane Ayurved Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current ROA % of 8.91% is 227.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current ROA % is 8.91%, which is 47% above median its own 10-year median of 6.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹228.09, compared to a current price of ₹187.00 — trading 18% below its estimated fair value. The current ROA % is 8.91%, which is 47% above median its 10-year median of 6.07 and 227.6% above the Drug Manufacturers industry median of 2.72. Vaidyane Ayurved Laboratories' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current ROA % is 8.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹187.00 is trading 18% below its estimated GF Value™ of ₹228.09.
GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:MADHAVBAUG:
ROA %: 8.91% (47% above median its 10-year median of 6.07)
GF Value™: ₹228.09 vs. price of ₹187.00 (18% below fair value)
Industry Position: 227.6% above the Drug Manufacturers median (#163 of 1005)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidyane Ayurved Laboratories Business Description
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
80GF Score
Get the complete analysis for NSE:MADHAVBAUG
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
